Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson’s disease

Use of glucagon-like peptide-1 receptor agonist or dipeptidyl peptidase 4 inhibitor has been shown to lower the incidence of Parkinson’s disease in patients with diabetes mellitus. Therefore, using these two treatments may help treat Parkinson’s disease. To further investigate the mechanisms of acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hai-Yang, Sun, Tong, Wang, Zhen, Li, Hong, Xu, Duo, An, Jing, Wen, Lu-Lu, Li, Jia-Yi, Li, Wen, Feng, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154509/
https://www.ncbi.nlm.nih.gov/pubmed/36751811
http://dx.doi.org/10.4103/1673-5374.360242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154509/
https://www.ncbi.nlm.nih.gov/pubmed/36751811
http://dx.doi.org/10.4103/1673-5374.360242

Ejemplares similares